Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 1, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
John Abbott Maintained (ARCT) at Buy with Decreased Target to $107 on, Mar 1st, 2022
John Abbott of Wells Fargo, Maintained "Arcturus Therapeutics Holdings Inc." (ARCT) at Buy with Decreased Target from $118 to $107 on, Mar 1st, 2022.
John has made no other calls on ARCT in the last 4 months.
There are 2 other peers that have a rating on ARCT. Out of the 2 peers that are also analyzing ARCT, 1 agrees with John's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Steven Seedhouse of "Raymond James" Upgraded from Sell to Hold on, Monday, January 31st, 2022
This is the rating of the analyst that currently disagrees with John
- Gena Wang of "Barclays" Maintained at Sell with Decreased Target to $31 on, Tuesday, November 9th, 2021
